TrialRMD open2024

Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND.

Ronald F van Vollenhoven et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.